TG4050
TG4050 is an individualized therapeutic vaccine
A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.
First positive data
from Phase I clinical trials

Initial data presented at the ASCO congress (June 2022)
Interview of the team and Pr Ottensmeier on the data (November 2022)
One cancer, one patient, one vaccine
With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies.
The treatment is based on an optimized MVA viral vector.
Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens) selected by NEC’s AI.
Once injected into the patient, this therapeutic vaccine will stimulate the patient’s immune defenses to allow the targeted destruction of cancer cells.
To carry out this project, Transgene relies on a unique expertise, a network of prestigious and recognized partners at every stage of product development and integrated manufacturing capabilities.
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
Clinical trials
Indication | Phase | |
---|---|---|
Ovarian cancer – after first-line surgery and chemotherapy | Phase I | More information |
HPV-negative head and neck cancers – after surgery and adjuvant therapy | Phase I | More information |
- September 20, 2023 - Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
- June 6, 2023 - Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- May 26, 2023 - Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstractand the poster
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation - Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation